Autonomix Stock Skyrockets After Obtaining Key Cancer Tech Patent
Autonomix Medical is skyrocketing Tuesday after securing U.S. Patent No. 12,433,670, expanding protection for its nerve-mapping platform.
Autonomix got official permission (called a patent) to be the only company allowed to use their special nerve-mapping tool for cancer work. This is good news because it protects their invention, but we don't know yet if the tool will actually help patients or make money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.